MedTrace Logo

CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors

NCT06195085 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2024-01-08

No results posted yet for this study

Summary

This study aimed to explore the long-term outcomes of CT-guided radioactive iodine-125 (I-125) seed implantation (RISI) for recurrent desmoid tumor.

A multicenter retrospective study reviewed 38 recurrent desmoid tumor patients receiving RISI from July 2013 to July 2021.The clinical outcomes including overall response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), adverse events (AEs), and symptom relief rate were statistically assessed.

Conditions

  • Brachytherapy
  • Desmoid Tumor
  • Radioactive Iodine-125 Seed Implantation

Interventions

RADIATION

CT-guided radioactive iodine-125 seed implantation

The CT-guided radioactive iodine-125 seed implantation procedure mainly consisted of preoperative treatment planning, intraoperative seed implantation and postoperative dosimetric evaluation. All procedures were performed as per relevant guidelines and regulations.

Sponsors & Collaborators

  • First Affiliated Hospital of the Army Medical University

    collaborator UNKNOWN

  • Shengli Oilfield Hospital

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Junjie Wang, M.D. · Peking University Third Hospital

Eligibility

Min Age
13 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2021-07-01
Completion
2023-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06195085 on ClinicalTrials.gov